Subscribe
Op-Eds

Novo Nordisk sued over weight-loss drug spin. Now it’s doing the exact same thing

By Arie Blitz
Published
Add Washington Examiner on Google

Novo Nordisk and Eli Lilly are battling for dominance in one of medicine’s largest and fastest-growing markets: drugs for obesity and weight loss.

On Monday, Novo announced encouraging results for its experimental drug CagriSema. In a Phase 3 study of patients with type 2 diabetes, CagriSema produced 12.4% average weight loss after 60 weeks, compared with 9.1% for Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Healthcare Lawsuits Medicine Ozempic Public relations Science Weight Loss Drugs